Robert W. Baird Lowers EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $33.00

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target trimmed by Robert W. Baird from $38.00 to $33.00 in a report released on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

EYPT has been the subject of several other research reports. Jefferies Financial Group started coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target for the company. Chardan Capital boosted their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, October 25th. Finally, Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $28.00.

EyePoint Pharmaceuticals Price Performance

EYPT stock opened at $10.49 on Monday. The firm has a 50 day simple moving average of $9.71 and a two-hundred day simple moving average of $9.91. The stock has a market cap of $561.42 million, a PE ratio of -5.25 and a beta of 1.50. EyePoint Pharmaceuticals has a one year low of $5.86 and a one year high of $30.99.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its position in shares of EyePoint Pharmaceuticals by 5.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after acquiring an additional 7,967 shares during the period. Intech Investment Management LLC purchased a new position in EyePoint Pharmaceuticals during the 3rd quarter valued at about $136,000. GSA Capital Partners LLP raised its position in EyePoint Pharmaceuticals by 129.6% during the 3rd quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock valued at $264,000 after purchasing an additional 18,616 shares during the last quarter. Greenwich Wealth Management LLC lifted its holdings in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after buying an additional 900 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after buying an additional 4,172 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.